5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Myelodysplastic O
syndrome/Acute O
Myeloid O
Leukemia O
: O
( O
MDS/AML O
) O
occurred O
in O
patients O
exposed O
to O
Lynparza O
, O
and O
some O
cases O
were O
fatal O
. O

Monitor O
patients O
for O
hematological O
toxicity O
at O
baseline O
and O
monthly O
thereafter O
. O

Discontinue O
if O
MDS/AML O
is O
confirmed O
. O

( O
5.1 O
) O
* O
Pneumonitis O
: O
occurred O
in O
patients O
exposed O
to O
Lynparza O
, O
and O
some O
cases O
were O
fatal O
. O

Interrupt O
treatment O
if O
pneumonitis O
is O
suspected O
. O

Discontinue O
if O
pneumonitis O
is O
confirmed O
. O

( O
5.2 O
) O
* O
Embryo-Fetal O
toxicity O
: O
Lynparza O
can O
cause O
fetal O
harm O
. O

Advise O
females O
of O
reproductive O
potential O
of O
the O
potential O
risk O
to O
a O
fetus O
and O
to O
avoid O
pregnancy O
. O

( O
5.3 O
, O
8.1 O
) O
5.1 O
Myelodysplastic O
syndrome/Acute O
Myeloid O
Leukemia O
Myelodysplastic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
/ O
Acute B-OSE_Labeled_AE
Myeloid I-OSE_Labeled_AE
Leukemia I-OSE_Labeled_AE
( O
MDS/AML O
) O
have O
been O
confirmed O
in O
6 O
out O
of O
298 O
( O
2 O
% O
) O
patients O
enrolled O
in O
a O
single O
arm O
trial O
of O
Lynparza O
monotherapy O
, O
in O
patients O
with O
deleterious O
or O
suspected O
deleterious O
germline O
BRCA B-Not_AE_Candidate
- I-Not_AE_Candidate
mutated I-Not_AE_Candidate
( I-Not_AE_Candidate
gBRCA I-Not_AE_Candidate
m I-Not_AE_Candidate
) I-Not_AE_Candidate
advanced I-Not_AE_Candidate
cancers I-Not_AE_Candidate
. O

In O
a O
randomized O
placebo O
controlled O
trial O
, O
MDS B-OSE_Labeled_AE
/ O
AML B-OSE_Labeled_AE
occurred O
in O
3 O
out O
of O
136 O
( O
2 O
% O
) O
patients O
with O
advanced O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
treated O
with O
Lynparza O
. O

Overall O
, O
MDS B-OSE_Labeled_AE
/ O
AML B-OSE_Labeled_AE
were O
reported O
in O
22 O
of O
2,618 O
( O
< O
1 O
% O
) O
patients O
treated O
with O
Lynparza O
. O

The O
majority O
of O
MDS B-OSE_Labeled_AE
/ O
AML B-OSE_Labeled_AE
cases O
( O
17 O
of O
22 O
cases O
) O
were O
fatal B-NonOSE_AE
, O
and O
the O
duration O
of O
therapy O
with O
Lynparza O
in O
patients O
who O
developed O
secondary O
MDS B-OSE_Labeled_AE
/cancer-therapy O
related O
AML B-OSE_Labeled_AE
varied O
from O
< O
6 O
months O
to O
> O
2 O
years O
. O

All O
patients O
had O
previous O
chemotherapy O
with O
platinum O
agents O
and/or O
other O
DNA O
damaging O
agents O
. O

Monitor O
complete O
blood O
count O
testing O
at O
baseline O
and O
monthly O
thereafter O
. O

Do O
not O
start O
Lynparza O
until O
patients O
have O
recovered O
from O
hematological B-NonOSE_AE
toxicity I-NonOSE_AE
caused O
by O
previous O
chemotherapy O
( O
< O
=CTCAE O
Grade O
1 O
) O
. O

For O
prolonged O
hematological B-NonOSE_AE
toxicities I-NonOSE_AE
, O
interrupt O
Lynparza O
and O
monitor O
blood O
counts O
weekly O
until O
recovery O
. O

If O
the O
levels O
have O
not O
recovered O
to O
CTCAE O
Grade O
1 O
or O
less O
after O
4 O
weeks O
, O
refer O
the O
patient O
to O
a O
hematologist O
for O
further O
investigations O
, O
including O
bone O
marrow O
analysis O
and O
blood O
sample O
for O
cytogenetics O
. O

If O
MDS B-NonOSE_AE
/ O
AML B-NonOSE_AE
is O
confirmed O
, O
discontinue O
Lynparza O
. O

5.2 O
Pneumonitis O
Pneumonitis B-OSE_Labeled_AE
, O
including O
fatal B-NonOSE_AE
cases O
, O
occurred O
in O
< O
1 O
% O
of O
patients O
treated O
with O
Lynparza O
. O

If O
patients O
present O
with O
new O
or O
worsening B-NonOSE_AE
respiratory I-NonOSE_AE
symptoms I-NonOSE_AE
such O
as O
dyspnea B-NonOSE_AE
, O
fever B-NonOSE_AE
, O
cough B-NonOSE_AE
, O
wheezing B-NonOSE_AE
, O
or O
a O
radiological O
abnormality O
occurs O
, O
interrupt O
treatment O
with O
Lynparza O
and O
initiate O
prompt O
investigation O
. O

If O
pneumonitis B-NonOSE_AE
is O
confirmed O
, O
discontinue O
Lynparza O
. O

5.3 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Lynparza O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
based O
on O
its O
mechanism O
of O
action O
and O
findings O
in O
animals O
. O

Olaparib O
was O
teratogenic B-NonOSE_AE
and O
caused O
embryo B-NonOSE_AE
- I-NonOSE_AE
fetal I-NonOSE_AE
toxicity I-NonOSE_AE
in O
rats O
at O
exposures O
below O
those O
in O
patients O
receiving O
the O
recommended O
human O
dose O
of O
400 O
mg O
twice O
daily O
. O

If O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
this O
drug O
, O
apprise O
the O
patient O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

Advise O
females O
of O
reproductive O
potential O
to O
avoid O
becoming O
pregnant B-NonOSE_AE
while O
taking O
Lynparza O
. O

If O
contraceptive O
methods O
are O
being O
considered O
, O
use O
effective O
contraception O
during O
treatment O
and O
for O
at O
least O
one O
month O
after O
receiving O
the O
last O
dose O
of O
Lynparza O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

